Skip to main content

Table 2 Demographic and baseline characteristics

From: Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion

Age, mean ± SD, years 57.4 ± 17.4
Male, n (%) 29 (40)
BMI, mean ± SD, kg/m2 25 ± 6
SAPS2, mean ± SD 33 ± 16
Comorbidities, n (%)  
 Active smoking 35 (49)
 COPD 23 (32)
 Other pulmonary disease 13 (18)
 Chronic heart disease 4 (6)
 Immunosuppression 30 (42)
Main cause of ICU admission, n (%)  
 Respiratory failure 34 (48)
  Pneumonia 20 (28)
  Acute interstitial pneumonia 7 (10)
  Acute chest syndrome 4 (6)
  Other 3 (4)
 Hemoptysis 19 (26)
 Thoracic surgery/traumatism 11 (15)
 Abdominal surgery 1 (1)
 Extra-pulmonary sepsis 2 (3)
Other 5 (7)
Pre-bronchoscopic respiratory parameters  
 SpO2, median [IQR], % 97 [94.8–99.2]
 RR, mean ± SD, per min 27 ± 9
 PaO2 < 60 mmHg, n (%) 17 (24)
 RR > 30 cycles per min, n (%) 34 (47)
Respiratory support, n (%)
  Oxygen therapy > 8L/min 30 (42)
  HFNC 15 (21)
  NIV 7 (10)
  Invasive mechanical ventilation 4 (6)
Pre-bronchoscopic hemodynamic parameters  
 MAP, median [IQR], mmHg 93 [83–101]
 HR, mean ± SD, beat per min 99 ± 21
  1. BMI: body mass index, SAPS2: Simplified Acute Physiologic Score, COPD: chronic obstructive pulmonary disease, SpO2: oxygen saturation by pulse oximetry, RR: respiratory rate, PO2: arterial partial pressure of oxygen, HFNC: high-flow humidified oxygen therapy through nasal cannula, NIV: non-invasive ventilation, MAP: mean arterial pressure, HR: heart rate
\